Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib

International Journal of Ophthalmology

Volumn 7, Issue 2, 2014, Pages 198-204

  Tian, Li Li ^a,b   Ren, Bing ^b   Gao, Xiao Wei ^b   Luo, Ying ^b   Cai, Yan ^b   Zhou, Kun ^a,b   Du, An Jie ^c   Zhao, Yong ^b  

^a SHIHEZI UNIVERSITY   (China)

^b No474 Hospital of Chinese PLA   (China)

^c Yuncheng Central Hospital   (China)

Author keywords

Neovascularization; Retinopathy of prematurity; Sorafenib; Tyrosine kinase inhibitors

Indexed keywords

EID: 84899868407     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.02.03     Document Type: Article

References (34)

1. Fleck BW, Mclntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev. 2008;84(2):83-88. [PubMed]
2. O'Connor AR, Spencer R, Birch EE. Predicting ng-term visual outcome in children with birth weight under l ooig. J AAPOS. 2007;ll(6):54l-545. [PubMed]
3. Simpson JL, Melia M, Yang MB, Buffenn AN, Chiang MF, Lambert SR. Current role of cryotherapy in retinopathy of prematurity: a report by the American Academy of Ophthalmogy. Ophthalmogy. 2012;l 19(4) 1873-877. [PubMed]
4. Aralikatti AK, Mitra A, Denniston AK, Haque MS, Ewer AK, Butler L. Is ethnicity a risk factor for severe retinopathy of prematurity?Arch Dis ChildFetal Neonatal Ed. 2010;95(3):Fl74-Fl76. [PubMed]
5. Holm strom G, van Wijngaarden P, Coster DJ, Williams KA. Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies. Br JOphthalmol. 2007;9l(l2):l7O4-l7O8. [PMCfree article] [PubMed]
6. Husain SM, Sinha K, BunceC, Arora P, ez W, Mun KS, Reddy MA, Adams GG. Relationships between maternal ethnicity, gestational age, birth weight, weight gain, andsevere retinopathy of prematurity. J Pediatr. 2013;l63(l):67-72. [PubMed]
7. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Lu GI, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005 56(4) :511-5 24. [PubMed]
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, andanggenesis. Am JPathol. 19955146(5):l029-1039. [PMCfree article] [PubMed]
9. Stone J, Itin A, An T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Develpment of retinal vasculatureis mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expressn by neuroglia. JNeurosci. 1995515(73:4738-4747. [PubMed]
10. Bromberg-White JL, Boguslawski E, Hekman D, Kort E, Duesbery NS. Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin. Invest Ophthalmol Vis Sci. 2011;52(l2):8979-8992. [PubMed]
11. McLeod DS, TaomotoM, Cao J, Zhu Z, Witte L, Lutty GA. 10calization of VEGF receptor-2 (KDR/Flk-l) and effects of b10cking itin oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43(2):474-482. [PubMed]
12. KinoseF, Roscilli G, Lamartina S,Anderson KD, Bonelli F, Spence SG, CilibertoG, Vogt TF, Holder DLToniatti C,Thut CJ. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol Vis. 2005;ll:366-373. [PubMed]
13. Rousseau B, Larrieu-Lahargue F, Bikfalvi A, Javerzat S. Involvement of fibroblast growth factors in choroidal anggenesis and retinal vascularization. Exp Eye Res. 2003;77(2):l47-l56. [PubMed]
14. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes H, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGFand PDGFsignaling enforces tumor vessel regressn by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;l8(2):338-340. [PubMed]
15. Hasumi Y, Ksowska-Wardga A, Furuhashi M, Ostman A, Heldin C, Hellberg C. Identification of a subset of pericytes that respondtocombination therapy targeting PDGFandVEGFsignaling. Int JCancer. 2007;l2l(l2):26o6-26l4. [PubMed]
16. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes andendothelial cells in thetumor vasculature with kinase inhibitors. JClin Invest. 2003;lll(9):l287-l295. [PMCfree article] [PubMed]
17. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res. 2007;l3(4):1098-106. [PubMed]
18. Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol. 2008;86(4):456-458. [PubMed]
19. 19-DiagoT, PulidoJS, Molina JR, Molina JR, Cet LC, LinkTP, Ryan EH., Jr. Ranibizumab combined with 10w-dose sorafenib for exudative age-related macular degeneration. MayoClin Proc. 2008;83(2):23l-234. [PMCfree article] [PubMed]
20. Smith LE, Wesowski E, McLellan A, Kostyk SK, D'AmatoR, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(l):101-lll. [PubMed]
21. Chen F, XieZ, Wu X, Du W, Wang J, Zhu J, Ji HQ, Wang YK. Intravitreal injection of soluble erythropoietin receptor exacerbates photoreceptor cell apoptosis in a rat model of retinal detachment. Curr Eye Res. 2012;37(l2):ll56-ll64. [PubMed]
22. ByfieldG, Budd S, Hartnett ME. The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci. 2009;50(7):336o-3365. [PMCfree article] [PubMed]
23. Chu Z, Dou G, WangY,Wu XJ, Zhang Y. Preliminary study of retinal pathogical features in preterm birth pups exposed to an animal model of oxygen-induced retinopathy in mice. Graef Arch Clin Exp Ophthalmol. 2013 5251(8) 1193 7-1943. [PubMed]
24. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL,Wilkinson-Berka JL. Retinal neovascularization is prevented by b10ckade of the renin-Angtensin system. Hypertensn. 200036(6):1099-l104. [PubMed]
25. Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996537(2) 1290-299. [PubMed]
26. Suzuma K, Takagi H, Otani A, Suzuma I, Honda Y. Increased expressn of KDR/Flk-l (VEGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvas Res. 1998;56(3):l83-l9l. [PubMed]
27. Motzer RJ, Nosov D, Eisen T, Bondarenkol, Lesovoy V, Lipatov O, Tomczak P, LyulkoO, Alyasova A, Harza M, Kogan M, Alexeev BY, Sternberg CN, Szczylik C, Zhang J, Strahs A, Esteves B, Slichenmyer W, Berkenblit A, Hutson TE. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III trial. JClin Oncol. 2013;3l(3o):379l-3799. [PubMed]
28. Strumberg D, Richly H, Hilger R A, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voltis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical andpharmacokineticstudy of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. JClin Oncol. 2005;23(s):965-972. [PubMed]
29. Kernt M, Liegl RG, Rueping J, Neubauer AS, Haritogu C, Lackerbauer CA, Eibl KH, Ulbig MW, Kampik A. sorafenib protects human optic nerve head astrocytes from light-induced overexpressn of vascular endothelial growth factor, platelet-derivedgrowth factor, andplacenta growth factor. Growth Factors. 20l0;28(3):2ll-220. [PubMed]
30. Kernt M, Thiele S, Hirneiss C, Neubauer AS, Lackerbauer CA, Wolf A, Eibl KH, Haritogu C, Ulbig MW, Kampik A. ZytoprotektiveundantianggeneWirkung des Mul tiki nase inhibitors sorafenib im retinal en Pigmentepithel. Der Ophthalmoge. 2011;108(5):445-45l. [PubMed]
31. Chung EJ, YooS, Lim HJ, By eon SH, Lee JH, Koh HJ. Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib. Br J Ophthalmol. 2009;93(7):958-963. [PubMed]
32. Park YH, Roh SY, LeeYC. Effect of sorafenib on experimental choroidal neovascularization in the rat. Clin Exp Ophthalmol. 2010;38(7):7l8-726. [PubMed]
33. Banin E, Dorrell MI, Aguilar E, Ritter MR, Aderman CM, Smith AC, Friedlander J, Friedlander M. T2-TrpRS inhibits preretinal neovascularization and enhances physgical vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006;47(5):2125-2134. [PubMed]
34. Ritter MR, Banin E, Moreno SK, Aguilar E, Dorrell MI, Friedlander M. My el oid progenitors differentiate intomicroglia and promote vascular repair in a model of ischemic retinopathy. JClin Invest. 2006;l 16(123:3266-3276. [PMCfree article] [PubMed]